Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis.
40 patients with American cutaneous leishmaniasis caused primarily by Leishmania braziliensis panamensis were treated with sodium stibogluconate in a double-blind, randomised controlled trial. Nine weeks after starting treatment, all 19 patients treated with 20 mg Sb/kg per day for twenty days were cured but 5 of 21 patients treated with 10 mg Sb/kg per day for twenty days had persistent active disease (p less than 0.05). Both treatment regimens were well tolerated and they were associated with a similar incidence of reversible toxic effects. Existing recommendations for therapy of American cutaneous leishmaniasis with sodium stibogluconate are inadequate for some patients, and higher doses are both safe and efficacious.
D000293:Adolescent; D000328:Adult; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005942:Gluconates / Q000008:administration & dosage*; D006801:Humans; D007592:Joint Diseases / Q000139:chemically induced; D007892:Leishmania braziliensis / Q000302:isolation & purification; D007893:Leishmania donovani / Q000302:isolation & purification; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D008889:Military Personnel; D011897:Random Allocation; D012449:Safety
D005942:Gluconates; D000967:Antimony Sodium Gluconate